Patents by Inventor Raymond E. Forslund

Raymond E. Forslund has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEGLUMINE SALTS OF THIENOPYRIMIDINES
    Publication number: 20210139499
    Abstract: Disclosed herein are thienopyrimidine meglumine salts according to Formula (I) used for treating or preventing heart failure:
    Type: Application
    Filed: October 20, 2020
    Publication date: May 13, 2021
    Inventors: Anuj K. Kumar, Raymond E. Forslund
  • Meglumine salts of thienopyrimidines
    Patent number: 10822346
    Abstract: Disclosed herein are thienopyrimidine meglumine salts according to Formula (I) used for treating or preventing heart failure:
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: November 3, 2020
    Assignee: CARDURION PHARMACEUTICALS, LLC
    Inventors: Anuj K. Kumar, Raymond E. Forslund
  • MEGLUMINE SALTS OF THIENOPYRIMIDINES
    Publication number: 20190315765
    Abstract: Disclosed herein are thienopyrimidine meglumine salts according to Formula (I) used for treating or preventing heart failure:
    Type: Application
    Filed: April 16, 2019
    Publication date: October 17, 2019
    Inventors: Anuj K. Kumar, Raymond E. Forslund
  • Salts, co-crystals, and polymorphs of an anxiolytic compound
    Patent number: 10266529
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 23, 2019
    Assignees: Bionomics Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND
    Publication number: 20170362230
    Abstract: The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 21, 2017
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Salts, co-crystals, and polymorphs of an anxiolytic compound
    Patent number: 9745296
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignees: BIONOMICS LIMITED, IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Vasu V. Sethuraman, Raymond E. Forslund, Song Xue, Rob Livingston, Ahmad Hashash
  • SALTS, CO-CRYSTALS, AND POLYMORPHS OF AN ANXIOLYTIC COMPOUND
    Publication number: 20160185770
    Abstract: The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: June 30, 2016
    Inventors: Bernard Luke FLYNN, Dharam PAUL, Andrew John HARVEY, Vasu V. SETHURAMAN, Raymond E. FORSLUND, Song XUE, Rob LIVINGSTON, Ahmad HASHASH
  • Processes and intermediates for preparing steric compounds
    Patent number: 8383858
    Abstract: This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 wherein the variables R1, R?1 and R2 are defined herein and the compound of Formula 1 has an enantiomeric excess (ee) of 55% or greater.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: February 26, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund
  • Preparation of protected alpha-keto beta-amino esters and amides
    Patent number: 8378124
    Abstract: The invention provides ?-sulfonamide ?-keto esters and amides in which the ?-keto is protected as a 1,3-dithiolane derivative. Also provided are methods for preparing such esters and amides and for incorporating them into peptides.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: February 19, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: William A. Nugent, Adam R. Looker, Raymond E. Forslund, Theodore A. Martinot, Cristian L. Harrison, Shereen Ibrahim
  • Deuterated hepatitis C protease inhibitors
    Patent number: 8247532
    Abstract: This invention relates to processes and intermediates for the preparation of salts of deuterated, enantiomericallv enriched alpha-amino beta-hydroxy acids of Formula 1 wherein the variables R1,R?1 and R?2 are defined herein, and wherein the process may comprise the steps of forming a salt of a compound of Formula 1, and crystallizing said salt to give a compound of greater than 55% enantiomeric excess.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: August 21, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, Youssef Bennani, Gregor Zlokarnik, Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund, Francois Maltais
  • Preparation of Protected Alpha-Keto Beta-Amino Esters and Amides
    Publication number: 20110213161
    Abstract: The invention provides ?-sulfonamide ?-keto esters and amides in which the ?-keto is protected as a 1,3-dithiolane derivative. Also provided are methods for preparing such esters and amides and for incorporating them into peptides.
    Type: Application
    Filed: December 30, 2010
    Publication date: September 1, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: William A. Nugent, Adam R. Looker, Raymond E. Forslund, Theodore A. Martinot, Cristian L. Harrison, Shereen Ibrahim
  • DEUTERATED HEPATITIS C PROTEASE INHIBITORS
    Publication number: 20110071074
    Abstract: A deuterated ?-ketoamido steric specific compound of the formula wherein D denotes a deuterium atom on a steric specific carbon atom.
    Type: Application
    Filed: November 24, 2010
    Publication date: March 24, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert B. Perni, Youssef Bennani, Gregor Zlokarnik, Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund, Francois Maltais
  • Processes and intermediates for preparing steric compounds
    Publication number: 20100298568
    Abstract: This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 wherein the variables R1, R?1 and R2 are defined herein and the compound of Formula 1 has an enantiomeric excess (ee) of 55% or greater.
    Type: Application
    Filed: August 4, 2010
    Publication date: November 25, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund